JADEITE MEDICINES

Eiichi Takahashi joined CBC Group as an Operating Partner in February 2020. In July of the same year, he established Jadeite Medicines Inc., and became the representative director, President, and CEO.

Prior to joining CBC Group, he was appointed as General Manager of Japan, VP for Amgen Inc. in 2013. He established Astellas Amgen Biopharma K.K. in the same year and developed the corporate organization as the representative director and the president, applied for approval and launched new drugs. Prior to joining Amgen, he joined Pfizer Japan in 2002 and took various responsibilities as the Cardiovascular Group Director, VP-Corporate Officer (Medical Department Head), a member of the board & Corporate Officer (Oncology Business Unit Head) of Pfizer Japan, and Specialty Care Business Unit, Medical Affairs Head of the Asia Pacific region of Pfizer Inc.

Denny has been with Jadeite Medicines since 2021 and became director March 2024. With more than 15 years of experience in the healthcare industry, Denny has broad experience in business and corporate development including in-licensing, out-licensing, capital raising, and mergers and acquisitions. Prior to joining CBC Group, he was most recently a Senior Director of Corporate and Business Development at Spectrum Pharmaceuticals, executing various key transactions for the company. Before that, he worked on Wall Street as an investment banker focused on the healthcare industry at JMP Securities, Canaccord Genuity and Houlihan Lokey.

Hayato Watanabe brings a wealth of entrepreneurship and investment expertise to CBC, being involved in private equity, venture financing and investment banking for over 20 years. Prior to joining CBC, Hayato was Head of Asia at Locust Walk, a global life science transaction firm where he led a number of global biopharma partnerships. Prior to Locust Walk, Hayato was Venture Partner at Eight Roads Ventures Japan, a proprietary investment arm of Fidelity International Limited, where he was heading its healthcare investments for Japan. During his time, he invested in state-of-the art technologies in gene editing and regenerative medicine. Prior to Eight Roads, Hayato was Director of the Investment Group at Innovation Network Corporation of Japan (INCJ) a government backed private equity investment company, making a number of investments in areas of CNS, ophthalmology and various therapeutic indications. Hayato has also extensive private equity experience as Director at Merrill Lynch Global Private Equity and as Associate at Shinsei Bank Private Equity where he was involved in numerous restructuring and leveraged buyout investments. Hayato started his career at Nikko Salomon Smith Barney (current Citigroup) in the mergers and acquisitions group based in Tokyo.

Hayato also co-founded of Fermenstation Co., Ltd. a sustainable bio-alcohol and bio-material company with his wife Lina.

Hiroyuki Achiwa joined Jadeite Medicines November 2021 as Chief Medical Officer. Hiroyuki is a respiratory physician and oncologist and has also been deeply involved in the pharmaceutical industry for nearly 20 years. Prior to joining Jadeite Medicines, Hiroyuki was the Head of Hematology and Oncology at Bristol Myers Squibb (former Celgene). Prior to Bristol Myers Squibb, Hiroyuki held a number of positions being engaged in clinical development in hematology and oncology at Novartis, Takeda Bio, and Merck Serono. Prior to the pharmaceutical industry, Hiroyuki was engaged in clinical practice, basic/clinical research, and clinical trials, and eventually studied abroad in the United States to conduct pharmacology and drug discovery research in oncology.

Junko Yamada joined Jadeite Medicines Group as advisor in June 2021. She held key medical positions in Pfizer Japan as Director of Regulatory Affairs, and Director of Pharmacovigilance for Marketed Products. Most recently, she served as Senior Director, Corporate Quality and Safety Assurance, and Chief Pharmaceutical Officer of Pfizer Japan.

Shinichi Kodato has joined Jadeite Medicines Group as advisor in November 2022. During his distinguished career he has held key positions at Tanabe Seiyaku (currently Mitsubishi Tanabe Pharma), Bushu Pharma, Chugai Pharmaceutical, Amgen Astellas Biopharma (Head of CMC/Supply Chain/QA), and Mitsui Warehouse Holdings where he was involved in all aspects of pharmaceutical quality from discovery research to development, launch, storage, and distribution. He is recently a GMDP consultant supporting the development and launch of new drugs establishing and improving Pharmaceutical Quality System and Good Practices for his clients.